1963年Starzl首先在人体施用同种异体肝脏原位移植术。目前全世界已进行了此种手术275例以上,其中美国的Starzl移植组作了114例,占总数的40％,其次是英国的Calne移植组作了64例。一年生存率已分别达到29～50％,最长已存活6 2/3年以上。肝移植的临床进展较肾移植慢的原因有二:(1)肝功能衰竭后目前尚无确实有效的人工支持系统可供应用,病人不能等待可供 In 1963 Starzl first administered human allogeneic liver orthotopic transplantation. At present, more than 275 such procedures have been carried out in the world, including 114 in the U.S. Starzl transplant group, accounting for 40% of the total, followed by 64 in the Calne transplant group in the United Kingdom. One-year survival rates have reached 29 to 50%, the longest survival has been 6 2/3 years. The clinical progress of liver transplantation is slower than that of kidney transplantation for two reasons: (1) there is no effective and effective artificial support system available for liver failure, and patients can not wait for available